FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3206807534> ?p ?o ?g. }

• W3206807534 abstract "Abstract Importance Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to protect against coronavirus disease of 2019 (COVID-19) is recommended for patients with multiple sclerosis (pwMS). However, approximately 80% of all pwMS treated with anti-CD20 therapy (rituximab, ocrelizumab) or fingolimod have low or absent humoral immunity after vaccination with two doses of SARS-CoV-2 mRNA vaccines. The efficacy and safety of a third vaccine dose in this group is largely unknown. Objective To characterize the humoral immunogenicity and the safety of a third dose of mRNA-COVID-19 vaccine in anti-CD20-or fingolimod-treated pwMS with low or absent humoral immunity (i.e., anti-SARS-CoV-2 IgG <70 arbitrary units (AU) and <5 AU, respectively) after two vaccinations. Design, setting and participants 130 anti-CD20- or fingolimod-treated pwMS with low or absent humoral immunity despite full vaccination against SARS-CoV-2, received a third dose of SARS-CoV-2 mRNA vaccine. Humoral immunity (i.e., antibody response against SARS-CoV-2) and the frequency and characteristics of side-effects were analyzed in all participants. Exposures A third vaccine dose against SARS-CoV-2 with BNT162b2- or mRNA-1273-COVID-19 vaccine. Main outcomes and measures Patient- and treatment-specific variables were acquired using a digital questionnaire, the Norwegian Immunization Registry and hospital journals. Humoral immunity was assessed by measuring SARS-CoV-2 SPIKE receptor-binding domain (RBD) IgG response. Low/absent humoral immunity was assumed in cases of AU<70 after anti-SPIKE protein-based serology 3-5 weeks after revaccination. Results A third dose of SARS-CoV-2 mRNA vaccine increased anti-SARS-CoV-2 SPIKE RBD IgG levels significantly. The proportion of patients with assumed protective humoral immunity (anti-SARS-CoV-2 SPIKE RBD IgG > 70 AU) were 25% among patients using anti-CD20 therapy and 7% among those treated with fingolimod. No adverse events were registered during the study period. Conclusion and relevance A third dose of mRNA-COVID-19 vaccine was associated with significantly increased levels of anti-SARS-CoV-2 SPIKE RBD IgG, – and hence assumed protective humoral immunity - in anti-CD20- or fingolimod-treated pwMS with low or absent humoral immunity despite full vaccination. The effect of a third vaccine dose was limited and more prominent among those treated with anti-CD20 therapy." @default.
• W3206807534 created "2021-10-25" @default.
• W3206807534 creator A5008257338 @default.
• W3206807534 creator A5011867426 @default.
• W3206807534 creator A5015324446 @default.
• W3206807534 creator A5016248743 @default.
• W3206807534 creator A5018708728 @default.
• W3206807534 creator A5020332094 @default.
• W3206807534 creator A5027230556 @default.
• W3206807534 creator A5035479067 @default.
• W3206807534 creator A5039189508 @default.
• W3206807534 creator A5059222696 @default.
• W3206807534 creator A5060635452 @default.
• W3206807534 creator A5063197826 @default.
• W3206807534 creator A5070289679 @default.
• W3206807534 creator A5070888827 @default.
• W3206807534 creator A5073837493 @default.
• W3206807534 creator A5074239285 @default.
• W3206807534 creator A5076820474 @default.
• W3206807534 creator A5081128572 @default.
• W3206807534 creator A5083034843 @default.
• W3206807534 date "2021-10-18" @default.
• W3206807534 modified "2023-10-15" @default.
• W3206807534 title "Efficacy and safety of a third SARS-CoV-2 vaccination in multiple sclerosis vaccine non-responders" @default.
• W3206807534 cites W2910867209 @default.
• W3206807534 cites W2977883158 @default.
• W3206807534 cites W3037709082 @default.
• W3206807534 cites W3085326737 @default.
• W3206807534 cites W3121831652 @default.
• W3206807534 cites W3136018364 @default.
• W3206807534 cites W3137944655 @default.
• W3206807534 cites W3158831599 @default.
• W3206807534 cites W3164547793 @default.
• W3206807534 cites W3172882514 @default.
• W3206807534 cites W3176897911 @default.
• W3206807534 cites W3199091389 @default.
• W3206807534 cites W3206123618 @default.
• W3206807534 doi "https://doi.org/10.1101/2021.10.15.21264977" @default.
• W3206807534 hasPublicationYear "2021" @default.
• W3206807534 type Work @default.
• W3206807534 sameAs 3206807534 @default.
• W3206807534 citedByCount "6" @default.
• W3206807534 countsByYear W32068075342021 @default.
• W3206807534 countsByYear W32068075342022 @default.
• W3206807534 crossrefType "posted-content" @default.
• W3206807534 hasAuthorship W3206807534A5008257338 @default.
• W3206807534 hasAuthorship W3206807534A5011867426 @default.
• W3206807534 hasAuthorship W3206807534A5015324446 @default.
• W3206807534 hasAuthorship W3206807534A5016248743 @default.
• W3206807534 hasAuthorship W3206807534A5018708728 @default.
• W3206807534 hasAuthorship W3206807534A5020332094 @default.
• W3206807534 hasAuthorship W3206807534A5027230556 @default.
• W3206807534 hasAuthorship W3206807534A5035479067 @default.
• W3206807534 hasAuthorship W3206807534A5039189508 @default.
• W3206807534 hasAuthorship W3206807534A5059222696 @default.
• W3206807534 hasAuthorship W3206807534A5060635452 @default.
• W3206807534 hasAuthorship W3206807534A5063197826 @default.
• W3206807534 hasAuthorship W3206807534A5070289679 @default.
• W3206807534 hasAuthorship W3206807534A5070888827 @default.
• W3206807534 hasAuthorship W3206807534A5073837493 @default.
• W3206807534 hasAuthorship W3206807534A5074239285 @default.
• W3206807534 hasAuthorship W3206807534A5076820474 @default.
• W3206807534 hasAuthorship W3206807534A5081128572 @default.
• W3206807534 hasAuthorship W3206807534A5083034843 @default.
• W3206807534 hasBestOaLocation W32068075341 @default.
• W3206807534 hasConcept C106192422 @default.
• W3206807534 hasConcept C159047783 @default.
• W3206807534 hasConcept C159654299 @default.
• W3206807534 hasConcept C203014093 @default.
• W3206807534 hasConcept C22070199 @default.
• W3206807534 hasConcept C2776036978 @default.
• W3206807534 hasConcept C2776548049 @default.
• W3206807534 hasConcept C2779341262 @default.
• W3206807534 hasConcept C2780640218 @default.
• W3206807534 hasConcept C2780868878 @default.
• W3206807534 hasConcept C71924100 @default.
• W3206807534 hasConcept C8891405 @default.
• W3206807534 hasConceptScore W3206807534C106192422 @default.
• W3206807534 hasConceptScore W3206807534C159047783 @default.
• W3206807534 hasConceptScore W3206807534C159654299 @default.
• W3206807534 hasConceptScore W3206807534C203014093 @default.
• W3206807534 hasConceptScore W3206807534C22070199 @default.
• W3206807534 hasConceptScore W3206807534C2776036978 @default.
• W3206807534 hasConceptScore W3206807534C2776548049 @default.
• W3206807534 hasConceptScore W3206807534C2779341262 @default.
• W3206807534 hasConceptScore W3206807534C2780640218 @default.
• W3206807534 hasConceptScore W3206807534C2780868878 @default.
• W3206807534 hasConceptScore W3206807534C71924100 @default.
• W3206807534 hasConceptScore W3206807534C8891405 @default.
• W3206807534 hasLocation W32068075341 @default.
• W3206807534 hasOpenAccess W3206807534 @default.
• W3206807534 hasPrimaryLocation W32068075341 @default.
• W3206807534 hasRelatedWork W2022511384 @default.
• W3206807534 hasRelatedWork W3206123618 @default.
• W3206807534 hasRelatedWork W3213650876 @default.
• W3206807534 hasRelatedWork W4200375727 @default.
• W3206807534 hasRelatedWork W4205199251 @default.
• W3206807534 hasRelatedWork W4223916126 @default.
• W3206807534 hasRelatedWork W4283821855 @default.
• W3206807534 hasRelatedWork W4381570565 @default.

• next